Polmacoxib PCD Pharma Franchise Company

Cafoli Lifecare is a WHO-GMP certified Polmacoxib PCD pharma franchise company offering 3 Polmacoxib formulations across Capsule, Tablets. Every batch is manufactured in DCGI-approved, WHO-GMP compliant facilities and supplied to franchise partners on a monopoly basis with full promotional backing.

What is Polmacoxib?

Polmacoxib is a non-steroidal anti-inflammatory drug that acts as a selective cyclo-oxygenase-2 (COX-2) inhibitor with additional carbonic anhydrase binding, which contributes to its distribution and dosing profile. By selectively inhibiting COX-2 it reduces the prostaglandins that mediate inflammation and pain while largely sparing COX-1 in the gastric mucosa. It is used at low once-daily doses in the symptomatic treatment of osteoarthritis. Compound data is available on PubChem.

Polmacoxib Range Available for Franchise

Our Polmacoxib portfolio comprises 3 formulations available in the following dosage forms: Capsule, Tablets. Brand names, compositions, packing and net rates are shared on request with partners holding a valid Drug License. Contact us for the current Polmacoxib price list and stock position.

Therapeutic Applications of Polmacoxib

Polmacoxib is indicated for the relief of pain and inflammation in osteoarthritis, particularly of the knee and hip, and is used in patients requiring long-term NSAID therapy where gastric tolerability is a concern. Prescriptions come chiefly from orthopaedic surgeons and rheumatologists, and from pain-management specialists and consulting physicians managing chronic joint disease. It is a prescription-only medicine and carries the class cardiovascular precautions applicable to COX-2 inhibitors.

Why Polmacoxib is a High-Potential Molecule for Distributors

Polmacoxib is a newer entrant to the COX-2 class, and that is its commercial opening: prescriber interest in differentiated coxibs remains strong because osteoarthritis is lifelong and gastric intolerance is the main reason patients abandon conventional NSAIDs. Its very low once-daily dose is an easy detailing story for a medical representative, and because the molecule is not yet crowded with dozens of competing brands, a franchise partner can establish a brand with an orthopaedic panel before the segment saturates. Osteoarthritis therapy also means chronic repeat orders — the patient does not stop, so the prescription renews month after month.

Why Choose Cafoli Lifecare for Your Polmacoxib Franchise

Cafoli Lifecare works with over 1000+ franchise partners across India. Partners receive monopoly rights for their district or territory, WHO-GMP certified and DCGI-approved products, complete promotional inputs (visual aids, MR bags, samples, prescription pads, gifts), transparent net rates, and dependable dispatch. Our documentation and stock support are built for distributors who want to scale without operational friction.

References

1. PubChem — Polmacoxib compound record (NIH / NCBI)
2. MedlinePlus — Polmacoxib drug information (US National Library of Medicine)
3. PubMed — clinical literature on Polmacoxib